Saint Prex, Switzerland and Hørsholm, Denmark – November 15, 2022 Ferring Pharmaceuticals and Gubra entered into a collaboration agreement to further develop and characterize preclinical animal models of inflammatory bowel disease (IBD). The collaboration aims to advance our early pipeline…
Gubra once again wins the regional award title EY Entrepreneur of the year, Region Zealand In its justificatin, the EY committee recognizes Gubra’s development and enormous growth journey since our start-up in 2008. “They started up without investors and have…
Hørsholm, Denmark – September 20, 2022 Gubra, a leader in preclinical services within metabolic and fibrotic diseases and with a strong pipeline of novel discovery projects, today announced the election of Henriette Dræbye Rosenquist and Arndt Schottelius as new independent…
Hørsholm, Denmark 23 May 2022 Gubra, a leader in preclinical services within metabolic and fibrotic diseases, and with a strong pipeline of novel discovery projects, today released its 2021 annual report showing a 53% increase in revenue to DKK…
HØRSHOLM, Denmark – 10 February, 2022 Gubra ApS announced today a new research collaboration with Silence Therapeutics PLC to develop novel RNAi therapeutics for liver diseases with an unmet medical need. The collaboration aims to explore selected liver-directed targets identified…
Hørsholm, Denmark, January 11 2022 Quantitative 3D imaging using light sheet fluorescent microscopy is revolutionizing the way we look at pre-clinical endpoints and biodistribution. The imaging team at Gubra are at the forefront of this technological advancement. They came up…
HØRSHOLM, Denmark – 20 September, 2021 Gubra ApS announced today a new research collaboration and license agreement with Bayer AG for the development of novel peptide therapeutics to treat cardiorenal disease. Cardiorenal disease is an umbrella term for acute and chronic…
HØRSHOLM, Denmark – 12 August, 2021 Recently, the first healthy volunteer was dosed with GUB002496 in a clinical phase 1 trial. GUB002496 is a drug candidate aiming for weight reduction. The advancement of the first of three collaboration projects between…
Hørsholm, Denmark 28 May 2021 Gubra achieves strong growth results in its core CRO business. New models in the Kidney Space and in 3D imaging well received by the market. New AI/ML-based peptide target and drug discovery platform enables Gubra…
We are so proud of winning this prize. Gubra wins the EY Entrepreneur of the Year Sustainability Prize 2020. The jury recognizes Gubra for our clear attitude in CSR and active efforts for a better climate. “This year’s winner in the…